ArticleCell reports. Medicine2022
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports. Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 34 citations in OpenAlex.
- Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Crosstalk Between CTSBAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Chronic interferon signaling at baseline is associated with acquired resistance to immunotherapy in metastatic melanoma.Cell reports. Medicine · 2026Article
- Generalizable AI predicts immunotherapy outcomes across cancers and treatments.Nature medicine · 2026Article
- FFixR: a machine learning framework for accurate somatic mutation calling from FFPE RNA-seq data in cancer.Bioinformatics (Oxford, England) · 2026Article
- Article
- Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review.The British journal of dermatology · 2026Article
- Reference-guided computational framework identifies microenvironment metabolic subtypes and targets using pan-cancer single-cell datasets.Genome medicine · 2025Article
- 3D dynamic magnetic microfluidic chip for efficient plasma extracellular vesicle enrichment and machine learning-based multiparametric diagnosis of hepatocellular carcinoma.Journal of nanobiotechnology · 2025Article
- Dissecting Melanoma Ecosystem Heterogeneity from Molecular Characteristics to Genetic Variation at Single-Cell Resolution.International journal of molecular sciences · 2025Article
- Specific oncogene activation of the cell of origin in mucosal melanoma.Nature communications · 2025Article
- Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems.Lab on a chip · 2025Review
- Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy.iScience · 2025Article
- Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma.Science advances · 2025Article
- Observational
- Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.Science advances · 2024Article
- Stratified analysis identifies HIF-2bioRxiv : the preprint server for biology · 2024Article
- Tumour mutational burden: clinical utility, challenges and emerging improvements.Nature reviews. Clinical oncology · 2024Review
- Stat3-mediated Atg7 expression regulates anti-tumor immunity in mouse melanoma.Cancer immunology, immunotherapy : CII · 2024Article
- Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.Nature reviews. Cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 5 institutions in 2 countries.
Samuel S FreemanBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Moshe Sade-FeldmanBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jaegil KimBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Chip StewartBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Anna L K GonyeBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Arvind RaviBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Monica B ArniellaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Irena GushterovaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Thomas J LaSalleBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Emily M BlaumBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Keren YizhakDepartment of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 2611001, Israel.
Dennie T FrederickDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Tatyana SharovaDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Ignaty LeshchinerBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Liudmila ElaginaBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Oliver G SpiroBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Dimitri LivitzBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Daniel RosebrockBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
François AguetBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jian Carrot-ZhangBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gavin HaDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle 98109, WA, USA.
Ziao LinBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Jonathan H ChenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Michal Barzily-RokniDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Marc R HammondDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Hans C Vitzthum von EckstaedtDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Shauna M BlackmonDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Yunxin J JiaoBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Stacey GabrielBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Donald P LawrenceDepartment of Medical Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Lyn M DuncanDepartment of Pathology, Massachusetts General Hospital, Boston 02114, MA, USA.
Anat O Stemmer-RachamimovDepartment of Pathology, Massachusetts General Hospital, Boston 02114, MA, USA.
Jennifer A WargoDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Keith T FlahertyDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Ryan J SullivanDepartment of Medicine, Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.
Genevieve M BolandDepartment of Surgery, Massachusetts General Hospital, Boston 02115, MA, USA.
Matthew MeyersonBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Nir HacohenBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Broad Institute · USMassachusetts General Hospital · USFred Hutch Cancer Center · USTechnion – Israel Institute of Technology · ILThe University of Texas MD Anderson Cancer Center · US
Funding
Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3M(PQ3) The role of damaged DNA in inter-individual variation of tumor immunityR01CA208756 · NCI · BROAD INSTITUTE, INC. · PI HACOHEN, NIR · 2016 to 2020
$2.6MCancer Immunology Training GrantT32CA207021 · NCI · DANA-FARBER CANCER INST · PI WUCHERPFENNIG, KAI W · 2016 to 2020
$2.4MNCI NIH HHS R01 CA208756NCI NIH HHS T32 CA207021NCI NIH HHS U54 CA224068NHGRI NIH HHS T32 HG002295NHGRI NIH HHS U54 HG003067
Abstract
Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve survival prediction. However, integrating immune/tumor-intrinsic features using data from a single assay (DNA/RNA) remains underexplored. Here, we analyze whole-exome and bulk RNA sequencing of tumors from new and published cohorts of 189 and 178 patients with melanoma receiving CPB, respectively. Using DNA, we calculate T cell and B cell burdens (TCB/BCB) from rearranged TCR/Ig sequences and find that patients with TMB
Indexed as
MelanomaTranscriptomeExome SequencingHumansRNASequence Analysis, RNARNAcancer genomicscancer immunotherapyimmune checkpoint blockadeintegrative modelmelanomamelanoma subtypeT cell receptorTMBtumor mutational burden
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.